Follow The Short Interest: What’s Aeglea Biotherapeutics Incorporated (NASDAQ:AGLE) Upside After This Short Interest Decrease?

November 23, 2016 - By Linda Rogers   ·   0 Comments

Follow The Short Interest: What's Aeglea Biotherapeutics Incorporated (NASDAQ:AGLE) Upside After This Short Interest Decrease?

The stock of Aeglea Biotherapeutics Incorporated (NASDAQ:AGLE) registered a decrease of 34.91% in short interest. AGLE’s total short interest was 6,900 shares in November as published by FINRA. Its down 34.91% from 10,600 shares, reported previously. With 30,800 shares average volume, it will take short sellers 0 days to cover their AGLE’s short positions. The short interest to Aeglea Biotherapeutics Incorporated’s float is 0.11%. About 35,282 shares traded hands. Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has declined 38.47% since April 21, 2016 and is downtrending. It has underperformed by 43.80% the S&P500.

Aeglea BioTherapeutics, Inc. is a biotechnology company. The company has a market cap of $61.22 million. The Firm is engaged in the development of enzyme therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. It currently has negative earnings. The Company’s engineered human enzymes are designed to degrade specific amino acids in the blood.

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Ratings Coverage

Out of 4 analysts covering Aeglea BioTherapeutics (NASDAQ:AGLE), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aeglea BioTherapeutics has been the topic of 4 analyst reports since May 2, 2016 according to StockzIntelligence Inc. The firm has “Outperform” rating by BMO Capital Markets given on Monday, May 2. Wells Fargo initiated Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) on Monday, May 2 with “Outperform” rating. The firm has “Buy” rating by UBS given on Monday, May 2. The rating was initiated by Needham on Monday, May 9 with “Buy”.

AGLE Company Profile

Aeglea BioTherapeutics, Inc. is a biotechnology company. The Firm is engaged in the development of enzyme therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in IEM or to exploit the dependence of certain cancers on specific amino acids. The Company’s portfolio of products includes AEB1102, AEB3103, AEB2109 and AEB4104.

More notable recent Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on June 21, 2015, also Streetinsider.com with their article: “Aeglea BioTherapeutics (AGLE) Says Data Shows AEB3103 Suppresses Cancer Growth …” published on November 21, 2016, Businesswire.com published: “Aeglea Biotherapeutics Raises $44 Million in Series B Financing” on March 23, 2015. More interesting news about Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) were released by: 247Wallst.com and their article: “Can Shares of Aeglea BioTherapeutics Really More Than Double?” published on May 02, 2016 as well as Seekingalpha.com‘s news article titled: “Aeglea Biotherapeutics IPO: Wait For Larger April Deals” with publication date: April 04, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>